The global flow cytometry market size is estimated to reach USD 7,013.1 million by 2030, registering to grow at a CAGR of 8.41% from 2025 to 2030 according to a new report by Grand View Research, Inc. Technological advancements in the technique are introducing new and improved analytical tools, which include the development of microfluidic flow cytometry for Point-of-Care (PoC) testing. Furthermore, the rising prevalence of cancer, immunodeficiency disorders, and infectious diseases is driving the industry. In addition, increasing R&D investments in biopharmaceutical, life science, and biotechnology research activities have led to high demand for flow cytometry instruments. In recent years, a key focus has been on the development of portable microfluidic flow cytometry devices for PoC testing.
Microfluidics and flow cytometry together make a useful tool to measure multiple characteristics of biological samples. For instance, the easy availability of several microfluidics and miniaturized detectors have enabled the creation of microchip-based cytometers, such as optofluidic cytometer, imaging cytometer, and impedance cytometer. The development of microfluidic flow cytometry devices, which are cost-effective, portable, and compact, is beneficial. They are affordable in developing economies, such as Asia & Africa, and are enabling rapid growth in PoC testing applications. Furthermore, improvements in fluorescent dyes and the increasing utility of benchtop cytometers for academic research settings are expected to drive the industry.
Developments in multicolor flow cytometry are accelerating the adoption of the technique in novel drug development activities. For instance, in January 2020, DxFLEX, CE-IVD, a 13-colour clinical flow cytometry system was launched by Beckman Coulter Life Sciences in Europe. Similarly, easy cellular analysis by simultaneous evaluation of several parameters allows extensive use of such devices for contract research purposes. The COVID-19 pandemic also spurred innovations in the technique, as evidenced by the launch of new products in this domain. For instance, in July 2021, Metropolis Healthcare Ltd. launched CoviRisk-TBNK, a simple blood test to detect the risk status of a COVID-19 hospitalized patient.
It helps analyze patients’ need for ICU facilities or ventilation and aids in the reduction of stress on healthcare resources. The test is a flow cytometry-based lymphocyte subset assay and is IVD-approved. Such innovations are anticipated to fuel industry growth in the near future. Moreover, flow cytometry is a significant tool in listing and characterizing immune cells, and is also helpful in recognizing and validating underlying genetic defects. The technique is also used to observe and monitor the immune response of patients after stem cell transplantation, and hence, organ transplantation plays an important role in boosting industry growth. According to the WHO, around 50,000 stem cell transplantations are performed globally every year, and this number is expected to grow in the near future, broadening the scope of applications for the technique.
On the other hand, instruments are highly expensive, and hence, buyers in several developing countries may not be able to afford technologically advanced flow cytometry equipment. These instruments may cost over USD 100,000 and pose significant budgetary constraints for small- & mid-sized hospitals and clinical laboratories. However, some manufacturers, such as Sony, are trying to launch newer instruments using software to automate a number of processes. Such developments would not only improve the usability of the technique but also help bring down the average instrumentation cost-under USD 100,000-in the near future.
Request a free sample copy or view report summary: Flow Cytometry Market Report
The instrument segment led the market with the largest revenue share of 35.30% in 2024 with owing to higher penetration driven by technological developments.
Based on technology, the cell-based segment led the market with the largest revenue share of 76.16% in 2024.
Based on application, the clinical segment led the market with the largest revenue share of 45.34% in 2024.
Based on end use, the academic institutes segment accounted for the largest revenue share in 2024, driven by the extensive use of flow cytometry in cell biology and molecular diagnostics.
Grand View Research has segmented the global flow cytometry market based on product, technology, application, end-use, and region:
Flow Cytometry Product Outlook (Revenue, USD Million, 2018 - 2030)
Instruments
Cell Analyzers
Cell Sorters
Reagents & Consumables
Software
Accessories
Services
Flow Cytometry Technology Outlook (Revenue, USD Million, 2018 - 2030)
Cell-based
Bead-based
Flow Cytometry Application Outlook (Revenue, USD Million, 2018 - 2030)
Research
Pharmaceutical
Drug Discovery
Stem Cell
In Vitro Toxicity
Apoptosis
Cell Sorting
Cell Cycle Analysis
Immunology
Cell Viability
Others
Industrial
Clinical
Cancer
Organ Transplantation
Immunodeficiency
Hematology
Autoimmune Disorders
Flow Cytometry End-use Outlook (Revenue, USD Million, 2018 - 2030)
Commercial Organizations
Biotechnology Companies
Pharmaceutical Companies
CROs
Hospitals
Academic Institutes
Clinical Testing Labs
Flow Cytometry Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Mexico
Europe
UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
Australia
Thailand
South Korea
Latin America
Brazil
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
List of Key Players in Flow Cytometry Market
Danaher
BD
Sysmex Corporation
Agilent Technologies, Inc.
Apogee Flow Systems Ltd.
Bio-Rad Laboratories, Inc.
Thermo Fisher Scientific, Inc.
Stratedigm, Inc.
Miltenyi Biotec
Cytek Biosciences
Sony Group Corporation (Sony Biotechnology Inc.)
"The quality of research they have done for us has been excellent..."